Fundamental Analysis:
Overview
BioSig Technologies is an advanced digital signal processing technology company bringing never-before-seen insights to the treatment of cardiovascular arrhythmias. Through collaboration with physicians, experts, and healthcare leaders across the field of electrophysiology (EP), BioSig is committed to addressing healthcareās biggest priorities ā saving time, saving costs, and saving lives. The Companyās first product, the PURE EPā¢ System, an FDA 510(k) cleared non-invasive class II device, provides superior, real-time signal visualization allowing physicians to perform insight-based, highly targeted cardiac ablation procedures with increased procedural efficiency and efficacy. The PURE EPā¢ System is currently in a national commercial launch and an integral part of well-respected healthcare systems, such as Mayo Clinic, Texas Cardiac Arrhythmia Institute, Cleveland Clinic, and Kansas City Heart Rhythm Institute. In aĀ blinded clinical study recently published in the Journal of Cardiovascular Electrophysiology, electrophysiologists rated PURE EPā¢ as equivalent or superior to conventional systems for 93.6% of signal samples, with 75.2% earning a superior rating.